Long Run Efficacy...

 

This article is about ViiV's study of their long acting injected HIV medication, Cabenuva vs the daily Biktarvy.    The injected med is a dual & the other is a daily, oral, triple ingredient medication.   While I think this should've been done before going to market, at least it's being done now.

A point of concern is how much this research will include women in the study.  The article uses the word, "women," multiple times.  Most of the references are directly & actively referring to transgender women.  Only the most indirect statement just used "women".   HIV pharmaceutical research has been notably horrible about it's lack of inclusion of women in the studies.

We'll have to wait for the outcome.

Take care.

Cya...

Biktarvy

According to these articles, 1 & 2, the FDA has granted Gilead the go ahead with a new once daily regimen.  It will be called, Biktarvy.  Sounds like a German version of the  1960's show, Daktari.  It is very similar to the Descovy, which is basically an altered form of Truvada.   It has Bictegravir as an added component.  I couldn't find much on Bictegravir besides this pdf. 

The 1st article is very light, but holds a very important detail about this new med, the cost, which will be over $35,000 annually.  It's expected to quickly become the gold standard for HIV treatment.  Of course, it's a literal gold mine for Gilead.  The 2nd article goes much further details of the matter.

Give them a read.   This is medication has been approved & will be hitting the market soon. 

Cya...